Results were analyzed, Z test and chi square indicates that significant
difference has been observed after active medication. Coefficient of Variations
(C.V.) shows that when mean of active and placebo were compare to each other;
patients who were under “add-on” therapy of PEWF for one month, showed highly
significant. This indicates the prognostic effect of PEWF in patients with T2D
with MI. Total 40 patients of either gender with T2D and MI were included in
this study. Demographic information, Clinical and Biochemical investigation
related to T2D were processed in 4 ml fasting venous blood. All participants
were assigned in two groups of 20 each. One group were under “Add On” therapy
of Active Drug which includes Pomegranate extract of whole fruit (PEWF) (300 mg
twice daily for One Month), matching Placebo of same color, shape and size was
used as comparator agent for second group. The Drug was issued to the Patients
initially for 15 days after which they were recalled for clinical valuation,
compliance monitoring, adverse effect monitoring if any; and drug refill for
next 15 days. At the end of one month, the base line investigations were
repeated. Patients were followed for next 3 months; on 4 month level of HbA1C
was monitored to check the status of T2D. Hypoglycemic drugs; which are usually
prescribe to cure T2D are either too expensive or have sides effects on
Hematological, Liver and kidney functions. WHO recommends to use alternative
medicine to cure T2D because herbal products are natural and don’t have such
side effects. One of such herb is pomegranate; usually consumed as fruit. As
per Ayurvedic literature, Pomegranate seeds may cure T2D and pulps contain lots
of antioxidants. This prompted us to find out; whether the presence strong
antioxidants in pomegranate have any prognostic effects in patients with T2D?
So we prepared a Whole Fruit Extract of Pomegranate (PEWF) to investigate its
effect in patients with T2D. Diabetes Mellitus Type 2(T2D) is one of the
leading disease in worldwide. Approximately 177 million peoples in worldwide
are effected with T2D. T2D is a heterogeneous metabolic disorder, which is
characterized by hyperglycemia and cardiovascular complications. Pathogenesis
of T2D is absolute or relative deficiency of insulin and insulin resistance.
Patients with T2D are highly prone oxidative stress because hyperglycemia
depletes natural antioxidants. - See more at: .
No comments:
Post a Comment